Anti-Venom Market Size 2024-2028: Key Trends and Forecasts

The global anti-venom market is expected to experience significant growth, forecasted to increase by USD 444.7 million with a CAGR of 7.3% from 2023 to 2028. The demand for anti-venoms is being driven by several key factors, including the high prevalence of venomous bites and stings from snakes, spiders, scorpions, marine creatures, and other venomous species. These bites pose significant health risks, especially in exotic destinations and tropical or subtropical regions, which continue to see rising incidents. Furthermore, unmet medical needs and advancements in biotechnology are pushing for more effective and species-specific anti-venom.

For more details about the industry, get the PDF sample report for free

Market Segmentation

By Type:

1. Polyvalent Anti-Venoms
2. Monovalent Anti-Venoms
3. Others

By Geography:

• North America
  • US
  • Canada
• Asia
  • China
  • India
  • Japan
  • South Korea
• Europe
  • Germany
  • UK
  • France
  • Italy
• Rest of World (ROW)

Regional Market Trends

• North America: Contributes 41% to global market growth. The United States is a key player, with approximately 7,000 to 8,000 venomous snake bites annually, driving demand for anti-venoms.
• Asia: Countries like India, China, and Japan have a high incidence of venomous bites, contributing to substantial growth in the market.
• Europe: Germany, the UK, France, and Italy are seeing a rise in anti-venom demand due to increasing venomous species and medical emergencies.

Market Dynamics

Drivers

• High Prevalence of Venomous Bites and Stings: The growing incidence of venomous bites from snakes, spiders, scorpions, and marine creatures like jellyfish is increasing the demand for anti-venoms. For instance, the World Health Organization reports an estimated 5.4 million snakebites occur annually, with substantial fatalities.

Trends

• Unmet Medical Needs: The urgent need for anti-venoms, particularly in areas with limited healthcare access, is a major trend in the market. The COVID-19 pandemic has worsened the situation, as healthcare systems prioritized pandemic care over treating venomous bites.

Challenges

• High Cost of Anti-Venoms: One of the most significant challenges is the cost of anti-venoms. Prices can exceed USD 3,000 per vial in developed countries, and multiple vials are often required for a single treatment. This high cost limits access to these vital therapies, especially in low- and middle-income regions.

Get more details by ordering the complete report

Key Players

• Bharat Serums and Vaccines Ltd.
• Biological E. Ltd.
• Boehringer Ingelheim International GmbH
• CSL Ltd.
• Haffkine Bio Pharmaceutical Corp. Ltd.
• Incepta Vaccine Ltd.
• Merck KGaA
• MicroPharm Ltd.
• Ophirex
• Pfizer Inc.
• Rare Disease Therapeutics Inc.
• SERB Sarl
• Serum Institute of India Pvt. Ltd.
• Silanes
• VINS Bioproducts Ltd.